Clinical Significance of Mycobacterium kansasii Isolates from Respiratory Specimens

The clinical significance of Mycobacterium kansasii respiratory isolates is uncertain. The aims of this study were to determine the clinical relevance of M. kansasii isolates and to identify the clinical features and outcomes of M. kansasii lung disease. We reviewed the medical records of 104 patients from whom at least one respiratory M. kansasii isolate was obtained from January 2003 to July 2014 at Samsung Medical Center, South Korea. Of these 104 patients, 54 (52%) met the diagnostic criteria for nontuberculous mycobacterial lung disease; among them, 41 (76%) patients received antibiotic treatment for a median time of 15.0 months (interquartile range [IQR], 7.0–18.0 months). The remaining 13 (24%) without overt disease progression were observed for a median period of 24.0 months (IQR, 5.0–34.5 months). Patients with M. kansasii lung disease exhibited various radiographic findings of lung disease, including the fibrocavitary form (n = 24, 44%), the nodular bronchiectatic form (n = 17, 32%), and an unclassifiable form (n = 13, 24%). The fibrocavitary form was more common in patients who received treatment (n = 23, 56%), while the nodular bronchiectatic form was more common in patients with M. kansasii lung disease who did not receive treatment (n = 9, 70%). None of the patients with a single sputum isolate (n = 18) developed M. kansasii disease over a median follow-up period of 12.0 months (IQR, 4.0–26.5 months). In total, 52% of all patients with M. kansasii respiratory isolates exhibited clinically significant disease. Moreover, patients with M. kansasii lung disease displayed diverse radiographic findings in addition to the fibrocavitary form. The nodular bronchiectatic form was more common in patients with M. kansasii lung disease with an indolent clinical course. Thus, since the clinical significance of a single M. kansasii respiratory isolate is not definite, strict adherence to recommended diagnostic criteria is advised.

[1]  R. Wallace,,et al.  Thrice-weekly clarithromycin-containing regimen for treatment of Mycobacterium kansasii lung disease: results of a preliminary study. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  Robert Horsburgh,et al.  An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. , 2007, American journal of respiratory and critical care medicine.

[3]  R. Thomson.  Changing Epidemiology of Pulmonary Nontuberculous Mycobacteria Infections , 2010, Emerging infectious diseases.

[4]  Sang-Nae Cho,et al.  Mycobacterial genotypes are associated with clinical manifestation and progression of lung disease caused by Mycobacterium abscessus and Mycobacterium massiliense. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  J. Falkinham.  Reducing human exposure to Mycobacterium avium. , 2013, Annals of the American Thoracic Society.

[6]  D. van Soolingen,et al.  Clinical relevance of non-tuberculous mycobacteria isolated in the Nijmegen-Arnhem region, The Netherlands , 2009, Thorax.

[7]  F. Drobniewski,et al.  The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study , 2013, European Respiratory Journal.

[8]  A. Telenti,et al.  Clinical Implications of Mycobacterium kansasii Species Heterogeneity: Swiss National Survey , 2003, Journal of Clinical Microbiology.

[9]  G. Fantuzzi,et al.  Patients with nontuberculous mycobacterial lung disease exhibit unique body and immune phenotypes. , 2013, American journal of respiratory and critical care medicine.

[10]  C. Ki,et al.  Direct application of the PCR restriction analysis method for identifying NTM species in AFB smear-positive respiratory specimens. , 2008, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[11]  P. Jenkins.  The epidemiology of opportunist mycobacterial infections in Wales, 1952--1978. , 1981, Reviews of infectious diseases.

[12]  Young Kil Park,et al.  Clinical significance of nontuberculous mycobacteria isolated from respiratory specimens in Korea. , 2006, Chest.

[13]  Chong-Jen Yu,et al.  Pulmonary Infection and Colonization with Nontuberculous Mycobacteria, Taiwan, 2000–2012 , 2014, Emerging infectious diseases.

[14]  K. Lee,et al.  Clinical significance of the differentiation between Mycobacterium avium and Mycobacterium intracellulare in M avium complex lung disease. , 2012, Chest.

[15]  C. Ki,et al.  Distribution of Nontuberculous Mycobacteria by Multigene Sequence-Based Typing and Clinical Significance of Isolated Strains , 2014, Journal of Clinical Microbiology.

[16]  R. Wallace,,et al.  Activities of clarithromycin against eight slowly growing species of nontuberculous mycobacteria, determined by using a broth microdilution MIC system , 1992, Antimicrobial Agents and Chemotherapy.

[17]  R. Chaisson,et al.  Nontuberculous mycobacteria: defining disease in a prospective cohort of South African miners. , 1999, American journal of respiratory and critical care medicine.

[18]  K. Winthrop,et al.  Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease. , 2010, American journal of respiratory and critical care medicine.

[19]  D. Griffith.  Management of disease due to Mycobacterium kansasii. , 2002, Clinics in chest medicine.

[20]  D. R. Prevots,et al.  Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review. , 2015, Clinics in chest medicine.

[21]  D. van Soolingen,et al.  Nontuberculous Mycobacteria in Respiratory Tract Infections, Eastern Asia , 2011, Emerging infectious diseases.

[22]  Bethany S Davies,et al.  Non-tuberculous slow-growing mycobacterial pulmonary infections in non-HIV-infected patients in south London , 2012, Scandinavian journal of infectious diseases.

[23]  J. Ingen,et al.  Geographical distribution and clinical relevance of non-tuberculous mycobacteria in Croatia. , 2013, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[24]  K. Lee,et al.  Nodular bronchiectatic Mycobacterium avium complex pulmonary disease. Natural course on serial computed tomographic scans. , 2013, Annals of the American Thoracic Society.

[25]  D. Snider,et al.  The epidemiology of nontuberculous mycobacterial diseases in the United States. Results from a national survey. , 1987, The American review of respiratory disease.

[26]  A. Dingemans,et al.  Risk factors for mortality in patients with pulmonary infections with non-tuberculous mycobacteria: a retrospective cohort study. , 2015, Respiratory medicine.

[27]  C. Ki,et al.  Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease. , 2015, American journal of respiratory and critical care medicine.

[28]  J. Stout.  Evaluation and management of patients with pulmonary nontuberculous mycobacterial infections , 2006, Expert review of anti-infective therapy.

[29]  Chong-Jen Yu,et al.  Pulmonary Infection and Colonization with Nontuberculous Mycobacteria , 2014 .

[30]  M. Chung,et al.  Thin-Section CT Findings of Nontuberculous Mycobacterial Pulmonary Diseases: Comparison Between Mycobacterium avium-intracellulare Complex and Mycobacterium abscessus Infection , 2005, Journal of Korean medical science.

[31]  O. Brändli,et al.  Epidemiology and clinical significance of nontuberculous mycobacteria in patients negative for human immunodeficiency virus in Switzerland. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  J. Falkinham.  Ecology of Nontuberculous Mycobacteria—Where Do Human Infections Come from? , 2013, Seminars in Respiratory and Critical Care Medicine.

[33]  W. Koh,et al.  Identification of Mycobacterium species in direct respiratory specimens using reverse blot hybridisation assay. , 2014, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[34]  L. Fogan.  PPD antigens and the diagnosis of mycobacterial diseases. A study of atypical mycobacterial disease in Oklahoma. , 1969, Archives of internal medicine.

[35]  K. Winthrop,et al.  Update on the Epidemiology of Pulmonary Nontuberculous Mycobacterial Infections , 2013, Seminars in Respiratory and Critical Care Medicine.

[36]  L. Saiman,et al.  Epidemiology of Nontuberculous Mycobacteria in Patients without HIV Infection, New York City , 2008, Emerging infectious diseases.

[37]  J. Gerberding,et al.  Incidence and Clinical Implications of Isolation of Mycobacterium kansasii: Results of a 5-Year, Population-Based Study , 1998, Annals of Internal Medicine.

[38]  S. Pang.  Mycobacterium kansasii infections in Western Australia (1962-1987). , 1991, Respiratory medicine.

[39]  D. Shitrit,et al.  Clinical and radiological features of Mycobacterium kansasii and other NTM infections. , 2012, Respiratory medicine.

[40]  I. Kassis,et al.  Epidemiology and clinical significance of non-tuberculous mycobacteria isolated from pulmonary specimens. , 2013, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[41]  R. Wallace,,et al.  Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes , 2011 .

[42]  C. Ki,et al.  Increasing Recovery of Nontuberculous Mycobacteria from Respiratory Specimens over a 10-Year Period in a Tertiary Referral Hospital in South Korea , 2013, Tuberculosis and respiratory diseases.